Skip to main content

Cellectis Sells Human Stem Cell Subsidiary to Takara Bio

NEW YORK (GenomeWeb) – Cellectis today announced it is selling its stem cell-focused subsidiary Cellectis AB to Takara Bio for an undisclosed amount.

The sale is the final step in Cellectis' restructuring of its Tools and Services business unit, which it said had been incurring heavy losses. The unit had an operating loss of €14 million ($18.8 million) in 2013 before accounting for extraordinary depreciation and costs related to downsizing.

Cellectis AB focuses on applications of human embryonic stem cell-based products and technologies for the research market and industry. Cellectis said the sale is expected to result in a loss of about €5 million. It added that the deal, expected to be completed in the coming weeks, will allow it to concentrate on its immunotherapy products for cancer applications.

Takara Bio is a Japanese biotechnology firm focused on gene therapies, genetic engineering, and provides research tools for molecular biology, cell biology, and protein research.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.